Tvardi Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Tvardi Therapeutics Inc TVRD.OQ reported quarterly adjusted earnings of $1.00​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-13.32. The mean expectation of seven analysts for the quarter was for a loss of 57 cents per share. Wall Street expected results to range from -85 cents to -28 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Tvardi Therapeutics Inc's reported EPS for the quarter was $1.00​.

• The company reported quarterly net income of $4.17 million.

• Tvardi Therapeutics Inc shares had risen by 1.8% this quarter and gained 29.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 13.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Tvardi Therapeutics Inc is $55.00, about 56.8% above its last closing price of $23.74

This summary was machine generated from LSEG data August 14 at 08:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)